PATENT CLAIM ANALYSIS

Application Number: 15880575
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "145100"]

Abstract:
IL-6 antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.

Claim (Index 45):
The antibody or antigen binding fragment of  claim 44 , wherein the one or more mutations comprise one of H311A, H311E, H311N.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 86.0
- Lexical Diversity: 1.33333
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14508068', '13820278', '15034782', '14649297', '12100008']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7179944756083326
- 35 USC 102 Novelty (BERT): 0.5878681313747944
- Combined Prediction Score: 0.7049818411849789
- Mean Citation Score: 379.027802
- Max Citation Score: 557.0569
- Similarity Product: 374.7950235002877

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test